Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance.
Adenosine Deaminase
/ deficiency
Adolescent
Adult
Brain
/ diagnostic imaging
Child
Child, Preschool
Enzyme Activation
Female
Genetic Association Studies
/ methods
Genetic Predisposition to Disease
Genetic Variation
Genotype
Humans
Inheritance Patterns
Intercellular Signaling Peptides and Proteins
/ deficiency
Male
Mutation
Pedigree
Penetrance
Phenotype
Sequence Analysis, DNA
Exome Sequencing
Young Adult
Exome sequencing
deficiency of adenosine deaminase 2
genome sequencing
loss-of-function variants
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
02
03
2020
accepted:
29
06
2020
pubmed:
9
7
2020
medline:
14
9
2021
entrez:
9
7
2020
Statut:
ppublish
Résumé
Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disorder that manifests with fever, early-onset vasculitis, strokes, and hematologic dysfunction. This study aimed to identify disease-causing variants by conventional Sanger and whole exome sequencing in two families suspected to have DADA2 and non-confirmatory genotypes. ADA2 enzymatic assay confirmed the clinical diagnosis of DADA2. Molecular diagnosis was important to accurately identify other family members at risk. We used a variety of sequencing technologies, ADA2 enzymatic testing, and molecular methods including qRT-PCR and MLPA. Exome sequencing identified heterozygosity for the known pathogenic variant ADA2: c.1358A>G, p.Tyr453Cys in a 14-year-old female with a history of ischemic strokes, livedo, and vasculitis. No second pathogenic variant could be identified. ADA2 enzymatic testing in combination with quantitative RT-PCR suggested a loss-of-function allele. Subsequent genome sequencing identified a canonical splice site variant, c.-47+2T>C, within the 5'UTR of ADA2. Two of her unaffected siblings were found to carry the same two pathogenic variants. A homozygous 800-bp duplication comprising exon 7 of ADA2 was identified in a 5-year-old female with features consistent with Diamond-Blackfan anemia (DBA). The duplication was missed by Sanger sequencing of ADA2, chromosomal microarray, and exome sequencing but was detected by MLPA in combination with long-read PCR sequencing. The exon 7 duplication was also identified in her non-symptomatic father and younger sister. ADA2 pathogenic variants may not be detected by conventional sequencing and genetic testing and may require the incorporation of additional diagnostic methods. A definitive molecular diagnosis is crucial for all family members to make informed treatment decisions.
Identifiants
pubmed: 32638197
doi: 10.1007/s10875-020-00817-3
pii: 10.1007/s10875-020-00817-3
pmc: PMC7416912
mid: NIHMS1610080
doi:
Substances chimiques
Intercellular Signaling Peptides and Proteins
0
ADA2 protein, human
EC 3.5.4.4
Adenosine Deaminase
EC 3.5.4.4
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
917-926Subventions
Organisme : NICHD NIH HHS
ID : P50 HD103538
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA DE000695
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA HG200372
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA HG200373
Pays : United States
Références
Genet Med. 2019 Sep;21(9):2135-2144
pubmed: 30890783
Bone Marrow Transplant. 2017 Nov;52(11):1575-1576
pubmed: 28805790
Blood. 2017 Dec 14;130(24):2682-2688
pubmed: 28974505
Pathogenetics. 2008 Nov 03;1(1):4
pubmed: 19014668
Cold Spring Harb Mol Case Stud. 2018 Dec 17;4(6):
pubmed: 30559313
Nat Genet. 2002 Jan;30(1):97-101
pubmed: 11731797
Arthritis Rheumatol. 2016 Sep;68(9):2314-22
pubmed: 27059682
Genet Med. 2012 Jan;14(1):143-51
pubmed: 22237444
J Rheumatol. 2020 Jan;47(1):117-125
pubmed: 31043544
J Clin Immunol. 2019 Nov;39(8):842-845
pubmed: 31617030
Genome Res. 2011 Jun;21(6):974-84
pubmed: 21324876
N Engl J Med. 2014 Mar 6;370(10):911-20
pubmed: 24552284
Genome Res. 2018 Aug;28(8):1228-1242
pubmed: 29907612
J Allergy Clin Immunol. 2018 Apr;141(4):1534-1537.e8
pubmed: 29391253
Am J Hum Genet. 2012 Oct 5;91(4):597-607
pubmed: 23040492
Rheumatology (Oxford). 2016 May;55(5):902-10
pubmed: 26867732
J Rheumatol. 2015 Aug;42(8):1532-4
pubmed: 26233953
Proc Natl Acad Sci U S A. 2010 Jan 26;107 Suppl 1:1779-86
pubmed: 19805052
J Pediatr Hematol Oncol. 2017 Jul;39(5):e293-e296
pubmed: 28230570
Pediatrics. 2018 Sep;142(3):
pubmed: 30139808
Arthritis Rheumatol. 2019 Oct;71(10):1747-1755
pubmed: 31008556
Nat Methods. 2018 Jun;15(6):461-468
pubmed: 29713083
Nat Biotechnol. 2011 Sep 25;29(10):908-14
pubmed: 21947028
J Rheumatol. 2019 Aug;46(8):1059-1060
pubmed: 31092714
Mol Cytogenet. 2017 Aug 23;10:30
pubmed: 28852425
N Engl J Med. 2014 Mar 6;370(10):921-31
pubmed: 24552285
Ann Hum Genet. 2016 May;80(3):187-96
pubmed: 27000383
Clin Genet. 2019 Jun;95(6):732-733
pubmed: 30920658
Pediatr Blood Cancer. 2018 Apr;65(4):
pubmed: 29271561
BMC Genomics. 2014 Jun 09;15:449
pubmed: 24912484
J Allergy Clin Immunol. 2015 Jan;135(1):283-7.e5
pubmed: 25457153
Arthritis Rheumatol. 2017 Aug;69(8):1689-1700
pubmed: 28493328
N Engl J Med. 2019 Apr 18;380(16):1582-1584
pubmed: 30995379
Genome Biol. 2011 Sep 28;12(9):R95
pubmed: 21955857
Front Immunol. 2018 Jun 14;9:1361
pubmed: 29963054
J Pediatr. 2016 Oct;177:316-320
pubmed: 27514238
J Clin Immunol. 2016 Apr;36(3):179-86
pubmed: 26922074
Ann Rheum Dis. 2017 Oct;76(10):1648-1656
pubmed: 28522451
Trends Genet. 2015 Oct;31(10):587-599
pubmed: 26209074
Sci Rep. 2015 Aug 03;5:12742
pubmed: 26235669
J Allergy Clin Immunol. 2020 Jun;145(6):1664-1672.e10
pubmed: 31945408